Regen BioPharma Inc
Regen BioPharma Inc (RGBPP): 7 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.7 months
D/E -1.05 · 0% dilution
Lead: Phase 1/Phase 2
7 candidates
N/A
N/A
A transparent, data-derived signal for Regen BioPharma Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$346K
Cash
$271
Quarterly Burn
$63K
Runway
3.7 mo
Revenue
$59K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| dcellvax | Phase 1/Phase 2 |
| diffronc | Preclinical |
| duracar | Preclinical |
| hemaxellarate | Preclinical |
| hemaxellerate | Phase 1 |
| small molecule nr2f6 modulators | Preclinical |
| tcellvax | Phase 1 |
Frequently asked questions
How many drug candidates are in Regen BioPharma Inc's pipeline?
Regen BioPharma Inc (RGBPP) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Regen BioPharma Inc's lead drug candidate?
Regen BioPharma Inc's most advanced tracked candidate is dcellvax (Phase 1/Phase 2) for breast cancer.
What is Regen BioPharma Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Regen BioPharma Inc has approximately 3.7 months of cash runway.
What is Regen BioPharma Inc's market capitalization?
Regen BioPharma Inc's market capitalization is approximately $346K.
Who is the CEO of Regen BioPharma Inc?
Dr. David Raymond Koos DBA, Ph.D. is the chief executive officer of Regen BioPharma Inc (RGBPP).
Get the full picture on Regen BioPharma Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.